Explore our primary pharmaceutical ingredients, specialized peptides, and industrial fine chemical lines manufactured under strict international cGMP standards.
Gentolex Group delivers end-to-end small-molecule API synthesis, contract manufacturing, regulatory documentation, and strategic supply chain integration for pharmaceutical partners across 10+ countries.
Neratinib (HKI-272), chemically designated as (E)-N-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide, is a potent, oral, irreversible pan-tyrosine kinase inhibitor (TKI) targeting human epidermal growth factor receptor 1 (HER1/EGFR), HER2, and HER4. As a critical therapeutic agent in extended adjuvant treatment for early-stage HER2-overexpressed/amplified breast cancer and advanced metastatic settings, maintaining absolute chemical purity and polymorphic consistency is vital for downstream drug product efficacy.
As a leading OEM Neratinib Exporter and contract development and manufacturing organization (CDMO), Gentolex Group operates state-of-the-art synthetic chemistry facilities equipped with multi-stage reaction vessels, automated crystallization setups, and advanced containment isolation modules suitable for handling high-potency active pharmaceutical ingredients (HPAPIs).
Unlocking technological leadership, robust supply chain resilience, and global compliance for oncology drug products.
Our expansive industrial footprint features multi-purpose production workshops designed for scalable intermediate synthesis through to commercial-scale cGMP finished API isolation. Flexible reaction capacities from 50L to 5000L allow seamless technical transfer from pilot trial to multi-ton batch execution.
Gentolex operates under rigid Quality Management Systems (QMS) aligned with US FDA, EMA, NMPA, and PMDA expectations. Complete CTD-format Drug Master Files (DMF), stability testing protocols under ICH conditions, and full trace-ability logs back every export shipment.
Beyond API exportation, we support global pharmaceutical developers through Finished Dosage Form (FDF) technology transfers, licensing-out arrangements, custom peptide synthesis, and turnkey lab/factory setup consultation services.
The oncology therapeutic space is witnessing rapid transformation driven by precision medicine, targeted TKIs, and antibody-drug conjugates (ADCs). The global market demand for HER2-positive breast cancer treatments continues to expand significantly, spurred by rising disease incidence, earlier screening diagnostic protocols, and expanded clinical indications for adjuvant and neo-adjuvant regimens.
In this dynamic landscape, Neratinib plays an irreplaceable clinical role. Unlike reversible TKIs, Neratinib forms a covalent, irreversible bond with Cys797 of EGFR and Cys805 of HER2, effectively silencing downstream MAPK and PI3K/Akt signaling cascades even in mutated or resistant cancer cell lines. Consequently, generic drug developers and regional pharmaceutical brands are actively seeking high-reliability OEM Neratinib suppliers and exporters capable of delivering consistent polymorphic Form A, controlled impurity profiles, and cost-effective bulk pricing to capitalize on upcoming patent expirations and tender requirements worldwide.
During the multi-step condensation and Michael addition reactions required for Neratinib Maleate synthesis, formation of related impurity G (dimeric degradation byproduct) and genotoxic alkylating intermediates poses a significant challenge for regulatory approval. Gentolex's optimized process chemistry utilizes precise catalytic pH-controlled crystallization technology and targeted solvent extraction, consistently maintaining toxic impurities below 0.05%, far surpassing standard USP/EP thresholds.
Global procurement teams face multifaceted challenges: strict regulatory audits, supply chain bottlenecks, strict cold-chain logistics requirements, and escalating manufacturing costs. Gentolex provides macro-level supply chain solutions designed to streamline international drug sourcing:
Our main business infrastructure focuses on supplying peptides APIs and Custom Peptides, FDF licensing out, Technical Support & Consultation, Product Line and Lab Setup, and integrated Sourcing & Supply Chain Solutions.
Supported by our factory construction footprint spanning 250,000 square meters, built to international specifications, offering flexible, scalable, and highly cost-effective chemical solutions.
Gentolex offers an extensive range of APIs and active intermediates for both development studies and commercial-scale applications under cGMP standards through long-term strategic collaborations.
For clients preferring to streamline vendor interactions, we deliver customized procurement services utilizing our comprehensive global supply chain networks.
Technical, regulatory, and commercial queries addressed by our expert chemical engineering and QA teams.
Stay updated with the latest technological developments in peptide synthesis, active pharmaceutical ingredients, and global health solutions.
Selank Acetate API is a synthetic heptapeptide active pharmaceutical ingredient composed of the amino acid sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Learn about its neuropharmacological research and production parameters...
View Details
As a professional Thymosin Beta-4 API manufacturer and supplier, we provide high-quality Tβ4 peptide API solutions for biotechnology companies and drug research organizations globally...
View Details
BPC-157 API is a synthetic pentadecapeptide gaining substantial attention in bio-peptide research due to its unique sequence and biological activity profile in cellular pathways...
View Details
With continuous developments in neuroscience and peptide synthesis technology, Semax API represents a key ACTH-derived synthetic peptide for scientific investigation...
View Details
SS-31 API, also known as Elamipretide, MTP-131, and Bendavia, is a synthetic mitochondria-targeting tetrapeptide designed to bind cardiolipin in the inner mitochondrial membrane...
View DetailsExplore additional specialized peptides, amino acid derivatives, and regulatory-approved intermediate products supplied globally.
